4.8 (631) · € 24.50 · En stock
New therapy with unique bacterial strain B. bifidum HI-MIMBb75 promises help for approximately 80 million Europeans suffering from irritable bowel syndrome1 World's largest clinical OTC irritable bowel syndrome trial investigating the efficacy of this particular strain published in the renowned medical journal The Lancet Gastroenterology & Hepatology2 Results show significant efficacy for all predominant irritable bowel syndrome symptoms and all subtypes while simultaneously improving patients’ quality of life2 (Gräfelfing/Munich, Germany) The world's largest OTC irritable bowel syndrome (IBS) trial comes up with remarkable results, which were recently published in the renowned medical journal The Lancet Gastroenterology & Hepatology. For the first time, leading German scientists around Prof. Dr. Peter Layer (Israelitic Hospital Hamburg) were able to prove the significant efficacy of a heat-inactivated bacterial strain on patients with IBS. Trial results show that B. bifidum HI-MIMBb75
Pharmacological and Clinical Treatment of Irritable Bowel Syndrome
CPhI worldwide: German probiotics company SYNformulas seeks partnerships to drive
Modulating the gut microenvironment as a treatment strategy for irritable bowel syndrome: a narrative review, Gut Microbiome
Frontiers The Microbiome and Irritable Bowel Syndrome – A Review on the Pathophysiology, Current Research and Future Therapy
Methods of Determining Irritable Bowel Syndrome and Efficiency of Probiotics in Treatment: A Review - ScienceDirect
A role for the gut microbiota in IBS Nature Reviews Gastroenterology & Hepatology
Cureus, Intestinal Spirochetosis and Chronic Diarrhea: A Case Report and Literature Review
Irritable bowel syndrome: Epidemiology, overlap disorders, pathophysiology and treatment
Irritable bowel syndrome - Wikipedia